drugset / Trial / NCT06202911

Effect of Oral N-Acetyl Cysteine in Prevention of Necrotizing Enterocolitis in Preterm Neonates With Feeding Intolerance

NCT06202911

Phase 4 Unknown 100 enrolled Ain Shams University
RandomizedParallel-groupSingle-blindPrevention

Summary

necrotizing enterocolitis is a dangerous disease that may be fatal especially in preterm neonates, the early features of the disease are symptoms of feeding intolerance and interruption of the baby's feeding plan , so prophylactic measures at this stage may help to prevent its progression and its complications. N-acetyl cysteine is an FDA- approved drug and has many uses in different diseases and in different age groups including neonates, it has a mucolytic and anti-inflammatory and anti-oxidant effects that are believed to break the bacterial biofilm which enables it to stick to the intestinal wall and also decrease the intestinal wall inflammation, therefore enhance the intestinal barrier and decrease the chance of bacterial invasion.

Timeline

Start
2023-01-01
Primary completion
2024-03-30
Completion
2024-03-30

Publications

  • Background undefined

Drugs

EvaluationDrugModalityDoseRoute
Comparator N-acetylcysteine Small molecule 20 mg Oral